title: [Administration of intravenous immunoglobulin is not free of risk in the neonatal period].
authors.forename: S G
authors.initials: SG
authors.lastname: Golombek
authors.forename: M
authors.initials: M
authors.lastname: Navarro
authors.forename: S
authors.initials: S
authors.lastname: Negre
authors.forename: M L
authors.initials: ML
authors.lastname: Matoses
authors.forename: A
authors.initials: A
authors.lastname: Ledo
authors.forename: P
authors.initials: P
authors.lastname: Saénz
authors.forename: M
authors.initials: M
authors.lastname: Vento
mesh_terms: D003093:Colitis, Ulcerative / Q000139:chemically induced*; D004899:Erythroblastosis, Fetal / Q000188:drug therapy; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects*; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D007262:Infusions, Intravenous; D007363:Intensive Care Units, Neonatal; D007567:Jaundice, Neonatal / Q000188:drug therapy*; D010789:Phototherapy; D012307:Risk Factors